학술논문

Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade
Document Type
article
Source
Genes & Development. 31(20)
Subject
Cancer
5.1 Pharmaceuticals
Development of treatments and therapeutic interventions
Animals
Antineoplastic Agents
Apoptosis
Autophagy
Benzamides
Cell Line
Tumor
Cell Respiration
Cell Survival
Heterocyclic Compounds
3-Ring
Humans
Lipid Droplets
Mice
Mitochondria
Neoplasms
Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phospholipase A2 Inhibitors
Phospholipids
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Pyrimidines
Signal Transduction
Tumor Cells
Cultured
autophagy
cancer
metabolism
phospholipid
resistance
signaling
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Developmental Biology
Language
Abstract
There is limited knowledge about the metabolic reprogramming induced by cancer therapies and how this contributes to therapeutic resistance. Here we show that although inhibition of PI3K-AKT-mTOR signaling markedly decreased glycolysis and restrained tumor growth, these signaling and metabolic restrictions triggered autophagy, which supplied the metabolites required for the maintenance of mitochondrial respiration and redox homeostasis. Specifically, we found that survival of cancer cells was critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids and free fatty acids to sustain fatty acid oxidation and oxidative phosphorylation. Consistent with this, we observed significantly increased lipid droplets, with subsequent mobilization to mitochondria. These changes were abrogated in cells deficient for the essential autophagy gene ATG5 Accordingly, inhibition of PLA2 significantly decreased lipid droplets, decreased oxidative phosphorylation, and increased apoptosis. Together, these results describe how treatment-induced autophagy provides nutrients for cancer cell survival and identifies novel cotreatment strategies to override this survival advantage.